[go: up one dir, main page]

PE20080844A1 - Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel - Google Patents

Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel

Info

Publication number
PE20080844A1
PE20080844A1 PE2007001262A PE2007001262A PE20080844A1 PE 20080844 A1 PE20080844 A1 PE 20080844A1 PE 2007001262 A PE2007001262 A PE 2007001262A PE 2007001262 A PE2007001262 A PE 2007001262A PE 20080844 A1 PE20080844 A1 PE 20080844A1
Authority
PE
Peru
Prior art keywords
lxr
prevention
treatment
skin aging
oxisterol
Prior art date
Application number
PE2007001262A
Other languages
English (en)
Inventor
Sunil Nagpal
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080844A1 publication Critical patent/PE20080844A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN MODULADOR LXR SELECCIONADO DE OXISTEROL, NO-OXISTEROL (NATURAL O SINTETICO), 22(R)HIDROXICOLESTEROL, N-(2,2,2-TRIFLUOROETIL)-N-{4-[2,2,2-TRIFLUORO-1-HIDROXI-1-(TRIFLUOROMETIL)ETIL]FENIL}BENCENO SULFONAMIDA, ENTRE OTROS. OPCIONALMENTE PUEDE CONTENER O NO UN LIGANDO, COMO, ACIDO ALL-TRANS RETINOICO, ACIDO 6-[3-(1-ADAMANTIL)-4-METOXIFENIL]-2-NAFTOICO, ENTRE OTROS; UN ANTIOXIDANTE; FILTRO SOLAR; RETINOIDES, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. EL MODULADOR DE LXR, INDUCE A LA EXPRESION DE LXR , LXRß, TIMP1, ASAH1, ENTRE OTROS, POR LO QUE DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO ANTI-ENVEJECIMIENTO DE LA PIEL
PE2007001262A 2006-09-19 2007-09-19 Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel PE20080844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84568506P 2006-09-19 2006-09-19

Publications (1)

Publication Number Publication Date
PE20080844A1 true PE20080844A1 (es) 2008-08-15

Family

ID=39110878

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001262A PE20080844A1 (es) 2006-09-19 2007-09-19 Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel

Country Status (5)

Country Link
US (1) US20080070883A1 (es)
AR (1) AR062911A1 (es)
PE (1) PE20080844A1 (es)
TW (1) TW200819145A (es)
WO (1) WO2008036238A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US9670244B2 (en) * 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
US20100048944A1 (en) * 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
CA2673513A1 (en) * 2006-12-19 2008-07-10 The Regents Of University Of California Inhibition of ppar gamma expression by specific osteogenic oxysterols
EP2146724A2 (en) * 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
US20100273816A1 (en) * 2007-05-18 2010-10-28 Ronald Charles Bernotas Quinazoline Compounds
CA2698928A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
JP2011505357A (ja) * 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
EP2235019A1 (en) * 2007-12-21 2010-10-06 Wyeth LLC Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
US20110034526A1 (en) * 2007-12-21 2011-02-10 Wyeth Llc Benzimidazole Compounds
AU2008345681A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds
JP2011507901A (ja) * 2007-12-21 2011-03-10 ワイス・エルエルシー ピラゾロ［１，５−ａ］ピリミジン化合物
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
US20110190285A1 (en) * 2008-09-19 2011-08-04 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
EP2349348A4 (en) * 2008-11-03 2013-06-26 Dermachip Inc COMPOSITIONS AND METHOD FOR REDUCING SIGNS FOR SKIN AGING
EP2352725A1 (en) * 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
JP2012509334A (ja) * 2008-11-19 2012-04-19 ワイス・エルエルシー 肝ｘ受容体（ｌｘｒ）モジュレーターとしての極性キナゾリン類
WO2011006087A1 (en) * 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
KR101766393B1 (ko) * 2010-11-30 2017-08-10 (주)아모레퍼시픽 블레오마이신 하이드로라제를 이용한 건조 피부 개선물질 스크리닝 방법
WO2012156420A1 (en) * 2011-05-17 2012-11-22 Chanel Parfums Beaute Large, hs6st2 or st8sia1 activators for preventing and/or attenuating skin ageing and/or hydrating skin
AU2012348700B2 (en) 2011-12-06 2015-08-27 Unilever Plc Skin anti-ageing composition
EP2847206A4 (en) 2012-05-07 2016-01-20 Univ California OXYSTEROL ANALOGUE OXY133 FOR INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNALING AND ADIPOGENESIS INHIBITION
EP2991652A4 (en) 2013-05-02 2016-12-07 Univ California BONE-LAYERED BONE-RELATED OSTEOGENIC OXYSTEROL AGENTS
CN105132358B (zh) * 2015-07-29 2019-12-06 苏州诺普再生医学有限公司 培养获得组织工程表皮的方法及其应用
US20190365784A1 (en) * 2015-12-30 2019-12-05 Raúl Enrique MASSONE Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
JP2022529409A (ja) * 2019-04-05 2022-06-22 ダームテック，インク． Ｕｖ損傷のモニタリングに使用するための新規な遺伝子分類子

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120805A (ja) * 1983-11-30 1985-06-28 Akira Kitano 皮膚化粧料
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
WO2003030857A1 (en) * 2001-10-04 2003-04-17 Unilever Plc Enhancing epidermal barrier development in skin
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
BR0215258A (pt) * 2001-12-21 2004-12-07 Pharmacia Corp Moduladores de receptor x de fìgado de tioéter aromático
US20050123580A1 (en) * 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
BR0311263A (pt) * 2002-05-24 2005-04-26 Pharmacia Corp Moduladores anilino receptores-x do fìgado
JP3694494B2 (ja) * 2002-07-02 2005-09-14 三井金属鉱業株式会社 車両スライド扉の動力装置
WO2004026816A1 (en) * 2002-09-17 2004-04-01 Pharmacia Corporation Aromatic liver x-receptor modulators
WO2004058175A2 (en) * 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
WO2004064769A2 (en) * 2003-01-21 2004-08-05 Hector Herrera Methods for making and using topical delivery agents
JP2006524234A (ja) * 2003-04-21 2006-10-26 タグラ バイオテクノロジーズ リミテッド アスコルビン酸の安定化誘導体
US20050009837A1 (en) * 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
RU2006124843A (ru) * 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
AR050279A1 (es) * 2004-08-03 2006-10-11 Wyeth Corp Indazoles como moduladores de lxr utiles en la preparacion de medicamentos pata el tratamiento de enfermedades cardiovasculares y mediadas por th1 y composiciones farmaceuticas que los contienen como principio activo.
BRPI0519620A2 (pt) * 2004-12-22 2009-02-25 F Hoffmamm La Roche Ag compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento terapÊutico e/ou profilÁtico de enfermidades que sço moduladas por agonistas alfa-lxr e/ou beta-lxr e utilizaÇço desses compostos
AU2006218661A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver X receptor modilators

Also Published As

Publication number Publication date
WO2008036238A2 (en) 2008-03-27
WO2008036238A3 (en) 2011-08-11
US20080070883A1 (en) 2008-03-20
TW200819145A (en) 2008-05-01
AR062911A1 (es) 2008-12-17

Similar Documents

Publication Publication Date Title
PE20080844A1 (es) Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel
ES2602986T3 (es) Nuevas composiciones cosméticas y/o farmacológicas y sus aplicaciones
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
AR032287A1 (es) Una composicion cosmetica para el cuidado de la piel y metodos cosmeticos que utilizan dicha composicion
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CL2007001873A1 (es) Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
BR0317275A (pt) Liberação controlada de uma substância ativa em um ambiente de gordura alta
BRPI0910874B8 (pt) formulação tópica para uso no tratamento tópico de uma condição da pele que resulta da produção de espécies reativas de oxigênio e/ou para a promoção da cicatrização de ferida tópica na pele de um indivíduo e uso da referida formulação
MA29851B1 (fr) Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit
CL2008000897A1 (es) Sal de arginina y uno o mas ácidos conjugados; composición de cuidado oral que comprende dicha sal; uso para reducir o inhibir la formacion de caries, desmineralizacion de los dientes; reducir la hipersensibilidad de los dientes, reducir o inhibir la gingivitos entre otras.
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
BRPI0811956A8 (pt) Solução tópica não aquosa de diclofenaco e processo para sua preparação
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
BR112014002769A2 (pt) método e kit depilatório
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2008000613A1 (es) Uso del acido (s,s)-(1-aminometil-3,4-dimetil-ciclopentil)-acetico para preparar un medicamento util para tratar tinnitis en un mamifero.
ES2564172T3 (es) Utilización de una composición cosmética para el cuidado de las pieles grasas
RU2009101326A (ru) Препарат для наружного применения на кожу, содержащий тритерпеновую кислоту
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.

Legal Events

Date Code Title Description
FD Application declared void or lapsed